Medicure Inc V.MPH

Many of these clinical test results

[Checkout]

are known before the test is administered. It is like Viagara. Do you think the company did not know that V gave you a erection, before the new use test of the heart drug, Viagara.

AGG is an old drug, probably much older than V. And they found another use for it.  They went into this test with great expectation of good results, or why spend the money testing it. Good news on the horizon. 120 of the randomized patients, did better using Tirofiban (AGG) than the Cangrelor. LOL That would be the best news.

Again, AGG will be the cheaper drug.


"Pharmacodynamic testing will be performed at several time points to test the investigators' study hypotheses: 1) Cangrelor will have similar inhibitory effect to Tirofiban (non-inferiority of Cangrelor compared with Tirofiban); 2) Compared with Prasugrel, Cangrelor and Tirofiban will achieve more prompt and enhanced platelet inhibitory effects (superiority of both Tirofiban and Cangrelor to integer Prasugrel); 3) Compared with integer loading dose of Prasugrel, chewed Prasugrel regimen will achieve more prompt and enhanced platelet inhibitory effects (superiority of chewed Prasugrel to integer Prasugrel). This study will provide insights on the pharmacodynamic effects of these drugs and will help clinicians choose the most appropriate treatment to avoid complications related to inadequate platelet inhibition in the early phase of patients with STEMI undergoing primary PCI."
 

[eSnowden]

Aggrastat and Prexxartan patents expire around the same time in 2023--instead of conducting trials on these drugs, he needs to be looking to expanding the product line...which he isn't doing. Friessen's mismanagemnt is getting comical--blows through a mountain of cash with nothing to show for it--and is now conducting trials on patent-expiring drugs.